UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 32,678 shares of the company's stock, valued at approximately $1,469,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.09% of Harrow as of its most recent filing with the SEC.
Several other hedge funds have also recently added to or reduced their stakes in HROW. First Turn Management LLC bought a new stake in shares of Harrow during the 3rd quarter worth $14,683,000. Rice Hall James & Associates LLC grew its holdings in Harrow by 23.1% during the 3rd quarter. Rice Hall James & Associates LLC now owns 314,881 shares of the company's stock valued at $14,157,000 after buying an additional 59,019 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Harrow by 195.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company's stock valued at $11,313,000 after buying an additional 166,602 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Harrow during the third quarter worth about $8,572,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Harrow during the third quarter worth about $5,864,000. Institutional investors own 72.76% of the company's stock.
Harrow Stock Performance
Shares of Harrow stock traded down $1.56 during trading hours on Tuesday, reaching $35.08. 337,959 shares of the stock traded hands, compared to its average volume of 503,286. The company has a 50 day moving average price of $45.84 and a 200 day moving average price of $36.31. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -37.81 and a beta of 0.69. Harrow, Inc. has a one year low of $9.13 and a one year high of $59.23. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on HROW. Craig Hallum upped their target price on Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a research note on Friday, October 4th. Lake Street Capital upped their target price on Harrow from $45.00 to $55.00 and gave the company a "buy" rating in a report on Friday, October 4th. Finally, B. Riley decreased their target price on Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a report on Wednesday, December 4th.
View Our Latest Analysis on HROW
About Harrow
(
Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
See Also
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
